Search Results - "Hodgson, Robert"

The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer's disease patients by Kennedy, Matthew E, Stamford, Andrew W, Chen, Xia, Cox, Kathleen, Cumming, Jared N, Dockendorf, Marissa F, Egan, Michael, Ereshefsky, Larry, Hodgson, Robert A, Hyde, Lynn A, Jhee, Stanford, Kleijn, Huub J, Kuvelkar, Reshma, Li, Wei, Mattson, Britta A, Mei, Hong, Palcza, John, Scott, Jack D, Tanen, Michael, Troyer, Matthew D, Tseng, Jack L, Stone, Julie A, Parker, Eric M, Forman, Mark S

“…β-Amyloid (Aβ) peptides are thought to be critically involved in the etiology of Alzheimer's disease (AD). The aspartyl protease β-site amyloid precursor…”
Get more information

The assessment and appraisal of regenerative medicines and cell therapy products: an exploration of methods for review, economic evaluation and appraisal by Hettle, Robert, Corbett, Mark, Hinde, Sebastian, Hodgson, Robert, Jones-Diette, Julie, Woolacott, Nerys, Palmer, Stephen

“…The National Institute for Health and Care Excellence (NICE) commissioned a 'mock technology appraisal' to assess whether changes to its methods and processes…”
Get full text

Methodological challenges for the evaluation of clinical effectiveness in the context of accelerated regulatory approval: an overview by Woolacott, Nerys, Corbett, Mark, Jones-Diette, Julie, Hodgson, Robert

“…Regulatory authorities are approving innovative therapies with limited evidence. Although this level of data is sufficient for the regulator to establish an…”
Get full text

Intensive behavioural interventions based on applied behaviour analysis (ABA) for young children with autism: A cost-effectiveness analysis by Hodgson, Robert, Biswas, Mousumi, Palmer, Stephen, Marshall, David, Rodgers, Mark, Stewart, Lesley, Simmonds, Mark, Rai, Dheeraj, Le Couteur, Ann

“…Background The economic and social costs of autism are significant. This study evaluates the cost-effectiveness of early intensive Applied Behaviour Analysis…”
Get full text

Discovery of the 3‑Imino-1,2,4-thiadiazinane 1,1-Dioxide Derivative Verubecestat (MK-8931)–A β‑Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor for the Treatment of Alzheimer’s Disease by Scott, Jack D, Li, Sarah W, Brunskill, Andrew P. J, Chen, Xia, Cox, Kathleen, Cumming, Jared N, Forman, Mark, Gilbert, Eric J, Hodgson, Robert A, Hyde, Lynn A, Jiang, Qin, Iserloh, Ulrich, Kazakevich, Irina, Kuvelkar, Reshma, Mei, Hong, Meredith, John, Misiaszek, Jeffrey, Orth, Peter, Rossiter, Lana M, Slater, Meagan, Stone, Julie, Strickland, Corey O, Voigt, Johannes H, Wang, Ganfeng, Wang, Hongwu, Wu, Yusheng, Greenlee, William J, Parker, Eric M, Kennedy, Matthew E, Stamford, Andrew W

“…Verubecestat 3 (MK-8931), a diaryl amide-substituted 3-imino-1,2,4-thiadiazinane 1,1-dioxide derivative, is a high-affinity β-site amyloid precursor protein…”
Get full text

Devices for remote continuous monitoring of people with Parkinson's disease: a systematic review and cost-effectiveness analysis by Cox, Edward, Wade, Ros, Hodgson, Robert, Fulbright, Helen, Phung, Thai Han, Meader, Nicholas, Walker, Simon, Rothery, Claire, Simmonds, Mark

“…Parkinson's disease is a brain condition causing a progressive loss of co ordination and movement problems. Around 145,500 people have Parkinson's disease in…”
Get full text

Interventions based on early intensive applied behaviour analysis for autistic children: a systematic review and cost-effectiveness analysis by Rodgers, Mark, Marshall, David, Simmonds, Mark, Le Couteur, Ann, Biswas, Mousumi, Wright, Kath, Rai, Dheeraj, Palmer, Stephen, Stewart, Lesley, Hodgson, Robert

“…Early intensive applied behaviour analysis-based interventions are intensive interventions for autistic children that are often delivered on a one-to-one basis…”
Get full text

Ablative and non-surgical therapies for early and very early hepatocellular carcinoma: a systematic review and network meta-analysis by Wade, Ros, South, Emily, Anwer, Sumayya, Sharif-Hurst, Sahar, Harden, Melissa, Fulbright, Helen, Hodgson, Robert, Dias, Sofia, Simmonds, Mark, Rowe, Ian, Thornton, Patricia, Eastwood, Alison

“…A wide range of ablative and non-surgical therapies are available for treating small hepatocellular carcinoma in patients with very early or early-stage…”
Get full text

Selective internal radiation therapies for unresectable early-, intermediate- or advanced-stage hepatocellular carcinoma: systematic review, network meta-analysis and economic evaluation by Walton, Matthew, Wade, Ros, Claxton, Lindsay, Sharif-Hurst, Sahar, Harden, Melissa, Patel, Jai, Rowe, Ian, Hodgson, Robert, Eastwood, Alison

“…Hepatocellular carcinoma is the most common type of primary liver cancer. Treatment choice is dependent on underlying liver dysfunction and cancer stage…”
Get full text

Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework by Murphy, Peter, Glynn, David, Dias, Sofia, Hodgson, Robert, Claxton, Lindsay, Beresford, Lucy, Cooper, Katy, Tappenden, Paul, Ennis, Kate, Grosso, Alessandro, Wright, Kath, Cantrell, Anna, Stevenson, Matt, Palmer, Stephen

“…The first histology-independent marketing authorisation in Europe was granted in 2019. This was the first time that a cancer treatment was approved based on a…”
Get full text

Initial assessment and management of adults with suspected acute respiratory infection: a rapid evidence synthesis of reviews and cost-effectiveness studies by Wade, Ros, Deng, Nyanar Jasmine, Umemneku-Chikere, Chinyereugo, Harden, Melissa, Fulbright, Helen, Hodgson, Robert, Eastwood, Alison, Churchill, Rachel

“…This work was undertaken to inform a National Institute for Health and Care Excellence guideline on the initial assessment of adults with suspected acute…”
Get full text

Preladenant, a selective A2A receptor antagonist, is active in primate models of movement disorders by HODGSON, Robert A, BEDARD, Paul J, DARE, Aurelie, NEUSTADT, Bernard R, STAMFORD, Andrew W, HUNTER, John C, VARTY, Geoffrey B, KAZDOBA, Tatiana M, DI PAOLO, Therese, GRZELAK, Michael E, POND, Annamarie J, HADJTAHAR, Abdallah, BELANGER, Nancy, GREGOIRE, Laurent

Get full text

Preladenant, a selective A(2A) receptor antagonist, is active in primate models of movement disorders by Hodgson, Robert A, Bedard, Paul J, Varty, Geoffrey B, Kazdoba, Tatiana M, Di Paolo, Therese, Grzelak, Michael E, Pond, Annamarie J, Hadjtahar, Abdallah, Belanger, Nancy, Gregoire, Laurent, Dare, Aurelie, Neustadt, Bernard R, Stamford, Andrew W, Hunter, John C

“…Parkinson's Disease (PD) and Extrapyramidal Syndrome (EPS) are movement disorders that result from degeneration of the dopaminergic input to the striatum and…”
Get full text

Methods for selecting the best evidence to inform a NICE technology appraisal on selective internal radiation therapies for hepatocellular carcinoma by Wade, Ros, Sharif-Hurst, Sahar, Harden, Melissa, Walton, Matthew, Claxton, Lindsay, Hodgson, Robert, Eastwood, Alison

“…Systematic reviews of medical devices are particularly challenging as the quality of evidence tends to be more limited than evidence on pharmaceutical…”
Get full text

Updated Creutzfeldt–Jakob disease infection control guidelines: sifting facts from fiction by Hodgson, Robert A

Get full text

The dual orexin receptor antagonist, DORA‐22, lowers histamine levels in the lateral hypothalamus and prefrontal cortex without lowering hippocampal acetylcholine by Yao, Lihang, Ramirez, Andres D., Roecker, Anthony J., Fox, Steven V., Uslaner, Jason M., Smith, Sean M., Hodgson, Robert, Coleman, Paul J., Renger, John J., Winrow, Christopher J., Gotter, Anthony L.

“…Chronic insomnia is defined as a persistent difficulty with sleep initiation maintenance or non‐restorative sleep. The therapeutic standard of care for this…”
Get full text

The antinociceptive and anxiolytic-like effects of the metabotropic glutamate receptor 5 (mGluR5) antagonists, MPEP and MTEP, and the mGluR1 antagonist, LY456236, in rodents: a comparison of efficacy and side-effect profiles by Varty, Geoffrey B, Grilli, Mariagrazia, Forlani, Angelo, Fredduzzi, Silva, Grzelak, Michael E, Guthrie, Donald H, Hodgson, Robert A, Lu, Sherry X, Nicolussi, Elisa, Pond, Annamarie J, Parker, Eric M, Hunter, John C, Higgins, Guy A, Reggiani, Angelo, Bertorelli, Rosalia

“…Modulation of metabotropic glutamate receptor (mGluR) subtypes represents a novel approach for the treatment of neurological and psychiatric disorders. This…”
Get full text

The anxiolytic-like effects of the novel, orally active nociceptin opioid receptor agonist 8-[bis(2-methylphenyl)methyl]-3-phenyl-8-azabicyclo[3.2.1]octan-3-ol (SCH 221510) by Varty, Geoffrey B, Lu, Sherry X, Morgan, Cynthia A, Cohen-Williams, Mary E, Hodgson, Robert A, Smith-Torhan, April, Zhang, Hongtao, Fawzi, Ahmad B, Graziano, Michael P, Ho, Ginny D, Matasi, Julius, Tulshian, Deen, Coffin, Vicki L, Carey, Galen J

“…Orphanin FQ/nociceptin (OFQ/N) is the endogenously occurring peptide ligand for the nociceptin opioid receptor (NOP) that produces anxiolytic-like effects in…”
Get more information

Characterization of a novel vasopressin V1b receptor antagonist, V1B-30N, in animal models of anxiety-like and depression-like behavior by Hodgson, Robert A., Mullins, Deborra, Lu, Sherry X., Guzzi, Mario, Zhang, Xiaoping, Bleickardt, Carina J., Scott, Jack D., Miller, Michael W., Stamford, Andrew W., Parker, Eric M., Varty, Geoffrey B.

“…Overactivity of the hypothalamic–pituitary–adrenal (HPA) axis has been linked to affective disorders such as anxiety and depression. Dampening HPA activity…”
Get full text

Antagonism of the adenosine A2A receptor attenuates akathisia-like behavior induced with MP-10 or aripiprazole in a novel non-human primate model by Bleickardt, Carina J., Kazdoba, Tatiana M., Jones, Nicholas T., Hunter, John C., Hodgson, Robert A.

“…Akathisia is a subset of the larger antipsychotic side effect profile known as extrapyramidal syndrome (EPS). It is associated with antipsychotic treatment and…”
Get full text